Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Among authors: bloch m. Lancet Infect Dis. 2024 Dec 5:S1473-3099(24)00667-4. doi: 10.1016/S1473-3099(24)00667-4. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39647494
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Among authors: bloch m. Open Forum Infect Dis. 2024 Oct 30;11(11):ofae638. doi: 10.1093/ofid/ofae638. eCollection 2024 Nov. Open Forum Infect Dis. 2024. PMID: 39582508 Free PMC article. Clinical Trial.
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C, Woo W, Bloch M, Cheung K, Griffin P, Mohan R, Deshmukh S, Arya M, Cumming O, Neville AM, McCallum Pardey TG, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Marcheschi A, Swan J, Smith G, Cho I, Glenn GM, Walker R, Mallory RM; Novavax 2019nCoV-311 Study Group. Bennett C, et al. Among authors: bloch m. Lancet Infect Dis. 2024 Jun;24(6):581-593. doi: 10.1016/S1473-3099(24)00077-X. Epub 2024 Mar 6. Lancet Infect Dis. 2024. PMID: 38460525 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 37970668
Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.
Athan E, Baber J, Quan K, Scott RJ, Jaques A, Jiang Q, Li W, Cooper D, Cutler MW, Kalinina EV, Anderson AS, Swanson KA, Gruber WC, Gurtman A, Schmoele-Thoma B; Study C3671006 Investigator Group. Athan E, et al. Clin Infect Dis. 2024 May 15;78(5):1360-1368. doi: 10.1093/cid/ciad707. Clin Infect Dis. 2024. PMID: 37992000 Free PMC article. Clinical Trial.
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
Bennett C, Rivers EJ, Woo W, Bloch M, Cheung K, Griffin P, Mohan R, Deshmukh S, Arya M, Cumming O, Neville AM, Pardey TM, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Buchanan A, Marcheschi A, Swan J, Smith G, Cho I, Glenn GM, Walker R, Mallory RM. Bennett C, et al. Among authors: bloch m. J Infect Dis. 2024 Jul 25;230(1):e4-e16. doi: 10.1093/infdis/jiad508. J Infect Dis. 2024. PMID: 39052718 Free PMC article. Clinical Trial.
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S. Mounzer K, et al. Among authors: bloch m. Clin Infect Dis. 2024 Nov 26:ciae522. doi: 10.1093/cid/ciae522. Online ahead of print. Clin Infect Dis. 2024. PMID: 39589133
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N; Glisten Study Group. Frith PA, et al. Thorax. 2015 Jun;70(6):519-27. doi: 10.1136/thoraxjnl-2014-206670. Epub 2015 Apr 3. Thorax. 2015. PMID: 25841237 Free PMC article. Clinical Trial.
976 results